1
|
Mills CE, Hafner M, Subramanian K, Chen C, Chung M, Boswell SA, Everley RA, Walmsley CS, Juric D, Sorger PK. Abstract PD1-12: Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib. Cancer Res 2019. [DOI: 10.1158/1538-7445.sabcs18-pd1-12] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
The recent introduction of small molecule inhibitors of cyclin-dependent kinases (CDK) 4/6 to the clinic has improved the treatment of hormone receptor positive breast cancer, and shown promise in other malignancies. The three clinically used CDK4/6 inhibitors, palbociclib, ribociclib, and abemaciclib, are reported to be broadly similar although recent data suggest that abemaciclib has distinct single-agent activity in patients and a unique adverse effects profile. Key questions are: How do these drugs differ at the molecular level? Should such differences inform their use in the clinic? Can these three agents be used interchangeably or should patient stratification differ between them? We use molecular and functional profiling by mRNA sequencing, mass spectrometry-based proteomics, and GR-based dose-response assays to obtain complementary views of the mechanisms of action of CDK4/6 inhibitors. We show that abemaciclib, but not ribociclib or palbociclib, is a potent inhibitor of kinases other than CDK4/6, including CDK1/Cyclin B, which appears to cause arrest in the G2 phase of the cell cycle, and CDK2/Cyclin E/A, which is implicated in resistance to palbociclib. We show that inhibition of these additional targets is accessible in a xenograft model. Whereas ribociclib and palbociclib induce cytostasis, and cells adapt to these drugs within 2-3 days of exposure, abemaciclib induces cell death and durably blocks cell proliferation. Abemaciclib is active even in retinoblastoma protein (pRb)-deficient cells in which CDK4/6 inhibition by palbociclib or ribociclib is completely ineffective. The degree of polypharmacology of small molecule drugs is increasingly viewed as an important consideration in their design, with implications for efficacy, toxicity, and acquired resistance. In the case of CDK4/6 inhibitors, we propose that abemaciclib polypharmacology elicits unique molecular responses. More generally, we propose that multi-omic approaches are required to fully elucidate the spectrum of targets relevant to drug action in tumor cells. We expect such understanding to assist in stratifying patient populations and ordering sequential therapies when resistance arises.
Citation Format: Mills CE, Hafner M, Subramanian K, Chen C, Chung M, Boswell SA, Everley RA, Walmsley CS, Juric D, Sorger PK. Omics profiling of CDK4/6 inhibitors reveals functionally important secondary targets of abemaciclib [abstract]. In: Proceedings of the 2018 San Antonio Breast Cancer Symposium; 2018 Dec 4-8; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2019;79(4 Suppl):Abstract nr PD1-12.
Collapse
Affiliation(s)
- CE Mills
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - M Hafner
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - K Subramanian
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - C Chen
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - M Chung
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - SA Boswell
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - RA Everley
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - CS Walmsley
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - D Juric
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - PK Sorger
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
2
|
Mills CE, Subramanian K, Hafner M, Chung M, Boswell SA, Everley RA, Juric D, Sorger PK. Abstract P2-07-03: Systematic characterization of kinase inhibitors reveals heterogeneity in responses by class and cell line. Cancer Res 2018. [DOI: 10.1158/1538-7445.sabcs17-p2-07-03] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]
Abstract
Abstract
Several publications have addressed concerns surrounding drug response screens by pointing out sources of variability and by presenting recommendations for better experimental methods and more robust analytical approaches. In the presented profiling effort, we integrated the latest advances in drug response measurement and focused on data diversity and quality rather than on breadth. We selected 32 breast cancer cell lines with a strong bias towards triple negative lines as well as 4 cell lines established from relevant patient-derived xenografts. We evaluated a panel of clinically relevant kinase inhibitors using a microscopy-based dose response assay to measure drug potency, and to quantify drug efficacy in terms of growth inhibition (GR metrics) and cell death. The use of the GR metrics to quantify drug sensitivity enabled us to identify and study differences between cytostatic and cytotoxic responses. This systematic dose response dataset is complemented by measurements of baseline transcript expression levels by mRNAseq, quantification of absolute abundance of ˜12,000 proteins, and relative phosphoprotein levels by shotgun mass spectrometry across all cell lines. Additionally, the baseline activity of transcription factors and kinases were inferred from the mRNA (using VIPER) and phosphoprotein (using kinase enrichment analysis) data, respectively. The complementarity of these multi-omics data has allowed us to address questions about the landscape of breast cancer cell lines such as: Where do the patient-derived lines lay relative to the conventional cell lines? How consistent are the landscapes defined by each dataset? How does integration across datasets provide mechanistic insight into signaling pathways that are active in each cancer subtypes? The measured and inferred baseline data were used to build predictors of the observed drug responses with the goal of identifying the biological processes responsible for the differences in sensitivity across drugs and cell lines. Overall the dataset that has been collected is a valuable resource for understanding drug response in triple negative breast cancer, and the molecular mechanisms that influence it.
Citation Format: Mills CE, Subramanian K, Hafner M, Chung M, Boswell SA, Everley RA, Juric D, Sorger PK. Systematic characterization of kinase inhibitors reveals heterogeneity in responses by class and cell line [abstract]. In: Proceedings of the 2017 San Antonio Breast Cancer Symposium; 2017 Dec 5-9; San Antonio, TX. Philadelphia (PA): AACR; Cancer Res 2018;78(4 Suppl):Abstract nr P2-07-03.
Collapse
Affiliation(s)
- CE Mills
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - K Subramanian
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - M Hafner
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - M Chung
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - SA Boswell
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - RA Everley
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - D Juric
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| | - PK Sorger
- Harvard Medical School, Boston, MA; Massachusetts General Hospital, Boston, MA
| |
Collapse
|
3
|
Li Y, Sun H, Zhang C, Liu J, Zhang H, Fan F, Everley RA, Ning X, Sun Y, Hu J, Liu J, Zhang J, Ye W, Qiu X, Dai S, Liu B, Xu H, Fu S, Gygi SP, Zhou C. Identification of translationally controlled tumor protein in promotion of DNA homologous recombination repair in cancer cells by affinity proteomics. Oncogene 2017; 36:6839-6849. [PMID: 28846114 PMCID: PMC5735297 DOI: 10.1038/onc.2017.289] [Citation(s) in RCA: 12] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/27/2017] [Revised: 06/09/2017] [Accepted: 07/13/2017] [Indexed: 01/21/2023]
Abstract
Translationally controlled tumor protein(TCTP) has been implicated in the regulation of apoptosis, DNA repair and drug resistance. However, the underlying molecular mechanisms are poorly defined. To better understand the molecular mechanisms underlying TCTP involved in cellular processes, we performed an affinity purification-based proteomic profiling to identify proteins interacting with TCTP in human cervical cancer HeLa cells. We found that a group of proteins involved in DNA repair are enriched in the potential TCTP interactome. Silencing TCTP by short hairpin RNA in breast carcinoma MCF-7 cells leads to the declined repair efficiency for DNA double-strand breaks on the GFP-Pem1 reporter gene by homologous recombination, the persistent activation and the prolonged retention of γH2AX and Rad51 foci following ionizing radiation. Reciprocal immunoprecipitations indicated that TCTP forms complexes with Rad51 in vivo, and the stability maintenance of Rad51 requires TCTP in MCF-7 cells under normal cell culture conditions. Moreover, inactivation of TCTP by sertraline treatment enhances UVC irradiation-induced apoptosis in MCF-7 cells, and causes sensitization to DNA-damaging drug etoposide and DNA repair inhibitor olaparib. Thus, we have identified an important role of TCTP in promoting DNA double-stand break repair via facilitating DNA homologous recombination processes and highlighted the great potential of TCTP as a drug target to enhance conventional chemotherapy for cancer patients with high levels of TCTP expression.
Collapse
Affiliation(s)
- Y Li
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - H Sun
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - C Zhang
- The 2nd Affiliated Hospital, Harbin Medical University, Harbin, China
| | - J Liu
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - H Zhang
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - F Fan
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - R A Everley
- Department of Cell Biology, Harvard Medical School, Boston, MA, USA
| | - X Ning
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - Y Sun
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - J Hu
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - J Liu
- The 2nd Affiliated Hospital, Harbin Medical University, Harbin, China
| | - J Zhang
- The 2nd Affiliated Hospital, Harbin Medical University, Harbin, China
| | - W Ye
- The 2nd Affiliated Hospital, Harbin Medical University, Harbin, China
| | - X Qiu
- The 2nd Affiliated Hospital, Harbin Medical University, Harbin, China
| | - S Dai
- The Tumor Hospital, Harbin Medical University, Harbin, China
| | - B Liu
- The Tumor Hospital, Harbin Medical University, Harbin, China
| | - H Xu
- Department of Clinical Laboratory, The First Affiliated Hospital, Dalian Medical University, Dalian, China
| | - S Fu
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| | - S P Gygi
- Department of Cell Biology, Harvard Medical School, Boston, MA, USA
| | - C Zhou
- The Laboratory of Medical Genetics, Harbin Medical University, Harbin, China
| |
Collapse
|